Background Lipoprotein(a) [Lp(a)] is a risk factor for atherosclerosis and increases with age. The purpose of this study was to determine the effect of ageing on Lp(a) for three different apo(a) phenotypes.
Introduction
Lipoprotein(a) [Lp(a)] is a macromolecular complex in human plasma that is assembled from a low-density lipoprotein (LDL) and a large glycoprotein called apolipoprotein(a) [apo(a)]. 1 Shortly after the discovery of the genetic Lp(a) system by Berg, 2 it was recognized that the levels of plasma Lp(a) range from 510 to 41000 mg/L among individuals, and higher Lp(a) levels increase the risk for atherosclerotic diseases. 3, 4 Apo(a) contains multiple repeated kringle-4 motifs. 5 Apo(a) isoforms varying in size from about 400 kDa to 4800 kDa were termed F, B, S1, S2, S3 and S4 according to their electrophoretic mobility relative to that of apo B. 6 Many studies have indicated that the apo(a) isoform is an important factor determining plasma Lp(a) levels, with an inverse correlation between the size of the apo(a) isoform and the plasma Lp(a) level. 6^8 The variation in apo(a) size is thought to account for approximately 40% of the variation in plasma Lp(a) levels based on protein phenotyping 9 and for about 70% based on DNA genotyping, 10 but causative factors for the rest of the variation are unclear. Furthermore, plasma Lp(a) levels di¡er substantially for each apo(a) phenotype. 6, 11, 12 Thus, these studies indicate that factors other than the apo(a) phenotype have an important e¡ect on plasma Lp(a) levels. Here, we report the e¡ect of ageing on the variation of plasma Lp(a) levels.
Materials and methods

Subjects
We examined 551 Japanese subjects referred to our clinic (237 men and 314 women, between the ages of 20 and 88 years). None of these subjects received medication that would in£uence plasma Lp(a) levels. Subjects with endocrine diseases or those with acute in£ammatory disease were excluded. A diagnosis of coronary heart disease (CHD) was based on the exercise electrocardiogram or a history of CHD.
Analytical methods
Plasma samples were obtained after an overnight fast and were stored at 7208C for up to 4 weeks. The frozen samples were thawed only once and examined
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within the same batch. Plasma Lp(a) levels were measured using an enzyme-linked immunosorbent assay kit (Biopool Co. Ltd, Sweden). The within-and inter-assay percentage coe¤cients of variation for the assay were 3¢2 and 8¢3, respectively. Apo(a) phenotypes were determined using a commercial kit (Sanwa Chemical Industry, Nagoya, Japan), which was based on a modi¢ed method of Utermann et al. 6, 7 Brie£y, 10 mL of plasma was mixed with 40 mL of sample bu¡er. After a 10-min incubation at 568C, 5 mL of the mixture was applied to a 4% polyacrylamide electrophoresis gel and run for 90 min at 20 mA. The proteins were then electrotransferred to a nitrocellulose membrane. Apo(a) phenotypes were immunostained using goat anti-human apo(a) antibodies and rabbit anti-goat IgG antibodies conjugated with horseradish peroxidase as the second antibody. Samples containing several apo(a) phenotypes were used for calibration. A heterozygote showing double bands was assigned as a homozygote for the phenotype with stronger staining. Samples showing no phenotype staining were not included in this study.
Statistical analyses
Plasma Lp(a) levels were compared using the Student's unpaired t-test after log transformation. Frequencies of plasma Lp(a) levels 5250 mg/L and of the association with CHD were compared using the G-test for a 262 contingency table. Values of P50 ¢05 were considered statistically signi¢cant. 
Results
The apo(a) phenotype distribution between 551 unrelated subjects was 84 (15¢2%) for the lowmolecular-weight (LMW) phenotype with the F, B or S1 isoform, 115 (20¢9%) for the intermediatemolecular-weight (IMW) phenotype with the S2 isoform and 352 (63 ¢ 9%) for the high-molecularweight (HMW) phenotype with the S3 or S4 isoform.
To evaluate the e¡ect of ageing on plasma Lp(a) levels, the subjects were divided into three groups according to age: young (20^39 years old, nˆ153) , middle-aged (40^59 years old, nˆ181) and elderly (560 years old, nˆ217). Table 1 shows plasma Lp(a) concentrations for the three age groups within each phenotype group. The mean plasma Lp(a) concentration decreased with increase in apo(a) molecular size in each age group, and increased with ageing in each apo(a) phenotype group. A statistically signi¢cant di¡erence was found between the young and the elderly age groups (Table1). The frequency of plasma Lp(a) concentrations 5250 mg/L exhibited the same tendency as that of the mean plasma Lp(a) concentrations ( Table 2) . We also examined the association of CHD with plasma Lp(a) concentrations in these subjects ( Table 3 ). The frequency of CHD increased with age in each phenotypic group. Signi¢cant di¡erences were found between the young and elderly age groups and also between the middle -aged and the elderly age groups in the IMW phenotype group (P50¢001 and P50 ¢05, respectively). Furthermore, in the elderly age group, the frequency of CHD for the LMWand the IMW phenotypes was signi¢cantly higher than for the HMW phenotype (P50¢001).
Discussion
It is of importance to determine the factors that control plasma Lp(a) levels, since high Lp(a) levels are known to be an independent risk factor for atherosclerosis. It is well known that there is an inverse correlation between the size of the apo(a) molecules and the plasma Lp(a) levels. 6^8 However, factors that a¡ect plasma Lp(a) levels remain poorly understood. The variation of apo(a) size can account for approximately 70% of the variation in plasma Lp(a) levels. 10 About 30% of the variation in plasma Lp(a) levels is thus a¡ected by genetic factors other than the structure of the apo(a) gene or environmental factors. Conditions including familial hypercholesterolaemia due to LDL receptor de¢ciency, 13 chronic renal failure 14 and acute in£ammatory disease 15 have been proposed to a¡ect plasma Lp(a) levels. Furthermore, several papers have reported the e¡ect of age, sex and menopausal status on plasma Lp(a) levels. 16^19 The mean plasma levels of Lp(a) increased with age in both sexes under the age of 60 or 70 years, 16, 17 and the proportion of subjects with high Lp(a) levels (5250 mg/L) also increased with age. 16 On the other hand, plasma Lp(a) levels in menopausal women have been reported to be signi¢cantly higher than those in premenopausal women, suggesting an e¡ect of oestrogen, 18, 19 although the e¡ect of androgen in men is not clear.
In this study, we compared plasma Lp(a) levels in each of the phenotype groups with age. The frequencies of apo(a) phenotypes observed in this study were similar to those reported for a healthy Japanese population, 20 indicating that our sample was representative of the general Japanese population.
In the present study, we demonstrated that the mean plasma Lp(a) levels increase with age independent of the phenotype. Furthermore, we showed that high Lp(a) concentrations (5250 mg/L) are more frequent in the elderly, suggesting that ageing a¡ects plasma Lp(a) levels.
Previous studies indicated that subjects with higher Lp(a) concentrations in association with the LMW apo(a) phenotypes have a high risk for CHD. 11, 12 In our present study, the frequency of CHD showed a tendency to increase with age in each phenotype group, although the strongest tendency was found in the LMW and the IMW groups. Since higher Lp(a) concentrations (5250 mg/L) were common in the middle -aged group for both LMW and IMW phenotype groups, the earlier exposure to high Lp(a) levels might explain the higher CHD frequency in subjects with LMW and IMW phenotypes.
In conclusion, ageing has a signi¢cant e¡ect on plasma Lp(a) concentrations; such an age-related elevation of Lp(a) may serve as a mechanism for atherosclerosis in the elderly.
